DEF: Nephros, Inc. Announces Annual Meeting of Stockholders and Director Nomination

Nephros, Inc. will hold its annual meeting virtually on June 16, 2025, to elect a director, ratify the appointment of its accounting firm, and approve executive compensation.

Summary

• Nephros, Inc. will hold its Annual Meeting of Stockholders virtually on June 16, 2025.
• The meeting will include the election of one director to a three-year term expiring in 2028.
• Stockholders will also vote to ratify the appointment of Baker Tilly US, LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• An advisory (non-binding) vote on the compensation of the company's named executive officers is also scheduled.
• The record date for determining stockholders entitled to vote is April 22, 2025.
• Stockholders can attend the virtual meeting online and vote their shares electronically.
• The Board of Directors recommends voting in favor of the director nominee, ratification of the accounting firm, and approval of executive compensation.
• Lisa Nettis is nominated as a Class II director.
• Alisa Lask will retire from the Board as of the conclusion of the Annual Meeting.
• The company's common stock outstanding as of April 22, 2025, was 10,600,350 shares.

Sentiment

Score: 7

Explanation: The document is primarily factual and procedural, outlining the agenda for the annual meeting and related corporate governance matters. The tone is professional and forward-looking, with a positive outlook on utilizing technology to enhance stockholder engagement.

Positives

• The company is utilizing technology to provide ready access, real-time communication, and cost savings for stockholders.
• The virtual Annual Meeting facilitates stockholder attendance and participation from any location.
• The Board of Directors has unanimously approved and recommends voting FOR the election of Ms. Nettis as a Class II director.
• The Board of Directors has unanimously approved and recommends the stockholders vote FOR the ratification of the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors has unanimously approved and recommends a vote FOR the approval of the compensation of our named executive officers as disclosed in this proxy statement.

Negatives

• Alisa Lask, the current Class II director, has decided not to stand for re-election and accordingly, will retire from the Board as of the conclusion of the Annual Meeting.

Risks

• If the appointment of Baker Tilly is not ratified by the stockholders, the Audit Committee will reconsider, but might not change, its decision to appoint Baker Tilly.
• There is a risk that the Board's leadership structure, or any other structure, will not be effective in all circumstances.

Future Outlook

The company aims to enhance stockholder value on an annual and long-term basis through its executive compensation arrangements.

Management Comments

• We are excited to continue to utilize the latest technology to provide ready access, real-time communication and cost savings for our stockholders and the Company.
• We believe that hosting a virtual Annual Meeting will facilitate stockholder attendance and participation from any location in the world.

Industry Context

The document reflects standard corporate governance practices, including the election of directors, appointment of auditors, and executive compensation, aligning with regulatory requirements and investor expectations.

Comparison to Industry Standards

• The virtual annual meeting format aligns with a growing trend among companies to leverage technology for increased accessibility and cost efficiency, similar to practices adopted by companies like Zoom and Microsoft.
• The director compensation structure, including annual retainers and meeting fees, is consistent with industry benchmarks for companies of similar size and market capitalization, as seen in peer companies like BioLife Solutions and CryoPort.
• The use of equity-based compensation for executives is a common practice to align management's interests with those of shareholders, mirroring strategies employed by companies such as Insulet and Tandem Diabetes Care.

Management Changes

Related Party Transactions

• During 2023, at the request of Mr. Amron, fees and options in the aggregate amount of approximately $29,545 earned in respect of services Mr. Amron rendered to us were directed to Wexford Capital LP.

Stakeholder Impact

• Shareholders are provided with the opportunity to vote on key corporate matters.
• Employees are covered by the Savings Incentive Match Plan for Employees Individual Retirement Account (SIMPLE IRA).

Next Steps

• Stockholders are encouraged to vote by proxy before the Annual Meeting.
• Stockholders can attend the virtual Annual Meeting on June 16, 2025.
• The Board of Directors will evaluate whether any actions are necessary to address the concerns of stockholders if there is any significant vote against the compensation of our named executive officers.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Director Election, Executive Compensation, Baker Tilly, Stockholders, Corporate Governance, Nephros